Cetera Investment Advisers grew its position in Clorox Co (NYSE:CLX) by 4.7% during the first quarter, Holdings Channel reports. The fund owned 2,956 shares of the company’s stock after acquiring an additional 132 shares during the quarter. Cetera Investment Advisers’ holdings in Clorox were worth $473,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in CLX. JPMorgan Chase & Co. boosted its position in Clorox by 5.2% in the third quarter. JPMorgan Chase & Co. now owns 1,019,248 shares of the company’s stock valued at $153,305,000 after buying an additional 50,360 shares in the last quarter. Legal & General Group Plc boosted its position in Clorox by 7.2% in the third quarter. Legal & General Group Plc now owns 821,194 shares of the company’s stock valued at $123,490,000 after buying an additional 55,435 shares in the last quarter. Contravisory Investment Management Inc. acquired a new position in Clorox in the fourth quarter valued at about $281,000. CX Institutional acquired a new position in Clorox in the fourth quarter valued at about $247,000. Finally, Pennsylvania Trust Co raised its stake in shares of Clorox by 13.9% in the fourth quarter. Pennsylvania Trust Co now owns 5,580 shares of the company’s stock worth $860,000 after acquiring an additional 682 shares during the last quarter. 77.91% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE CLX opened at $147.23 on Thursday. Clorox Co has a 1-year low of $116.17 and a 1-year high of $167.70. The stock has a market capitalization of $19.00 billion, a price-to-earnings ratio of 23.52, a P/E/G ratio of 4.34 and a beta of 0.31. The company has a quick ratio of 0.66, a current ratio of 1.10 and a debt-to-equity ratio of 2.93.

Clorox (NYSE:CLX) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $1.44 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.47 by ($0.03). The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.57 billion. Clorox had a return on equity of 108.82% and a net margin of 12.68%. The company’s quarterly revenue was up 2.2% on a year-over-year basis. During the same period last year, the firm earned $1.37 earnings per share. On average, equities research analysts anticipate that Clorox Co will post 6.29 earnings per share for the current year.

A number of equities analysts have weighed in on CLX shares. Credit Suisse Group started coverage on shares of Clorox in a research note on Wednesday, March 6th. They issued an “outperform” rating and a $172.00 target price for the company. BMO Capital Markets set a $175.00 target price on shares of Clorox and gave the stock a “buy” rating in a research note on Tuesday, February 5th. Barclays reaffirmed a “hold” rating and issued a $142.00 target price on shares of Clorox in a research note on Wednesday, February 6th. Wells Fargo & Co reaffirmed a “hold” rating and issued a $157.00 target price on shares of Clorox in a research note on Thursday, February 21st. Finally, JPMorgan Chase & Co. downgraded shares of Clorox from a “neutral” rating to an “underweight” rating and dropped their target price for the stock from $159.00 to $139.00 in a research note on Monday, April 8th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. Clorox has an average rating of “Hold” and an average target price of $149.57.

In related news, SVP Andrew J. Mowery sold 5,340 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $156.44, for a total transaction of $835,389.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2019/05/16/cetera-investment-advisers-grows-holdings-in-clorox-co-clx.html.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Featured Story: What is a Lock-Up Period?

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.